Arcus Biosciences
RCUS
57 hedge funds and large institutions have $313M invested in Arcus Biosciences in 2018 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 27 increasing their positions, 13 reducing their positions, and 11 closing their positions.
108% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 13
14% more capital invested
Capital invested by funds: $274M → $313M (+$38.7M)
0.09% more ownership
Funds ownership: 50.38% → 50.47% (+0.09%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
11% less funds holding
Funds holding: 64 → 57 (-7)
64% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$2.75M |
| 2 |
Millennium Management
New York
|
+$1.45M |
| 3 |
BlackRock
New York
|
+$1.28M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$1.26M |
| 5 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$548K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.26M |
| 2 |
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
|
-$2.25M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.07M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$734K |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$567K |
RCUS Hedge Fund Activity: Q3 2018 in Review
57 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q3 2018, worth a combined $313M — up 14% from $274M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of RCUS and 4 opened new positions — a net loss of 7 holders — while 13 trimmed existing stakes and 27 added.
The largest buyer was JP Morgan Chase, adding an estimated $2.75M. The largest seller was T. Rowe Price Associates, cutting an estimated $3.26M.
- 57 institutional investors held Arcus Biosciences (RCUS) as of Q3 2018, down from 64 in Q2 2018.
- Funds reported $313M of Arcus Biosciences stock for Q3 2018, up 14% quarter-over-quarter.
- 4 funds opened new Arcus Biosciences positions in Q3 2018 and 11 closed out, a net change of -7 holders.
- The largest Arcus Biosciences buyer in Q3 2018 was JP Morgan Chase, an estimated $2.75M added.
- The largest Arcus Biosciences seller in Q3 2018 was T. Rowe Price Associates, an estimated $3.26M sold.
Based on aggregated 13F filings for Q3 2018.